Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 635

1.
2.

Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.

Chapman MJ, Guérin M, Bruckert E.

Eur Heart J. 1998 Feb;19 Suppl A:A24-30. Review.

PMID:
9519339
3.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
4.

Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

Le Goff W, Guerin M, Chapman MJ.

Pharmacol Ther. 2004 Jan;101(1):17-38. Review.

PMID:
14729390
5.

Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Després JP, Lemieux I, Robins SJ.

Drugs. 2004;64(19):2177-98. Review.

PMID:
15456334
6.

The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.

Lamarche B, Lemieux I, Després JP.

Diabetes Metab. 1999 Sep;25(3):199-211. Review.

PMID:
10499189
7.

Metabolic syndrome and renal failure: similarities and differences.

Kaysen GA.

Panminerva Med. 2006 Sep;48(3):151-64. Review.

PMID:
17122751
8.

Abnormalities in metabolism of low density lipoproteins associated with coronary heart disease.

Grundy SM, Vega GL, Kesäniemi YA.

Acta Med Scand Suppl. 1985;701:23-37. Review.

PMID:
3907293
10.

The physiology of lipoproteins.

Tulenko TN, Sumner AE.

J Nucl Cardiol. 2002 Nov-Dec;9(6):638-49. Review.

PMID:
12466789
11.

Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.

Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G.

Biochem Soc Trans. 2003 Oct;31(Pt 5):1070-4. Review.

PMID:
14505482
12.
13.

Statins and diabetes.

Carmena R, Betteridge DJ.

Semin Vasc Med. 2004 Nov;4(4):321-32. Review.

PMID:
15861314
14.

Dyslipidemia of the metabolic syndrome.

Ruotolo G, Howard BV.

Curr Cardiol Rep. 2002 Nov;4(6):494-500. Review.

PMID:
12379172
15.

Lipoproteins and atherosclerosis.

Babiak J, Rudel LL.

Baillieres Clin Endocrinol Metab. 1987 Aug;1(3):515-50. Review.

PMID:
3330421
17.

The role of non-LDL:non-HDL particles in atherosclerosis.

Segrest JP.

Curr Diab Rep. 2002 Jun;2(3):282-8. Review.

PMID:
12643186
18.

Measurement issues related to lipoprotein heterogeneity.

Otvos JD, Jeyarajah EJ, Cromwell WC.

Am J Cardiol. 2002 Oct 17;90(8A):22i-29i. Review.

PMID:
12419478
19.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165

Supplemental Content

Support Center